ClinicalTrials.gg
RecruitingNCT05844514Updated Jun 13, 2025

COlorectal BReath Analysis (COBRA2)

An observational study in Colorectal Cancer, sponsored by Imperial College London. Recruiting at 5 sites in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
720
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Colorectal Neoplasms by Imperial College London — 6 open to participants now, 6 under way, none of them phase 3. Colorectal Neoplasms · Imperial College London.

Started
2022
the only one that year
Observational
6 of 13
3 open now
Registered
11th of 13
by date

Among the 13 studies in Colorectal Neoplasms by Imperial College London, this one is the only one that started in 2022, is one of 6 observational ones, and was the 11th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 13 studies in Colorectal Neoplasms by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colorectal Neoplasms by Imperial College London, or all of them as a file.
02

Study summary

Colorectal cancer (CRC) is the second most common cause of cancer death in the United Kingdom, with approximately 17,000 deaths per year. The five-year survival rate from CRC is only 10% when discovered at a late stage, but exceeds 90% if diagnosed early. Symptoms related to CRC can be non-specific, therefore the decision to refer for a colonoscopy can be challenging.

There is a clear need to improve earlier detection of CRC so that patients with CRC can be identified earlier and faster, enabling them to start treatment more quickly.

The study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that are specific to CRC. For patients with non-specific symptoms, this test would help GPs to identify those patients that may have underlying CRC, who would benefit from referral for specialised CRC tests.

Read the detailed description

The COBRA1 study initially assessed VOCs in CRC and identified a list of 14 VOC biomarkers for CRC and provided a detection model with an area under the receiver operating characteristic curve of 0.91, sensitivity of 83% and specificity of 88% in symptomatic patients.

COBRA2 aims to develop and validate the clinical prediction model (CPM) in the detection of CRC based on the breath test. An exploratory comparison between the breath test and faecal immunochemical test (FIT) will also be carried out to assess whether combining both tests improves diagnostic performance.

Methods: COBRA2 is be a prospective, multicentre validation study. The study team are recruiting the following patients:

The following groups of patients are being recruited:

i) Control group: symptomatic patients who are attending a planned colonoscopy referred under the suspected lower GI cancer pathway. Any patient who is found to have histologically-proven CRC on colonoscopy will be analysed as part of the CRC group.

ii) CRC group: patients who either have a confirmed diagnosis of colorectal adenocarcinoma according to a biopsy, or who are due to undergo surgical resection for suspected CRC (with histological confirmation to follow within three months).

Target recruitment is 720 patients (470 controls, 250 CRC), aiming for 576 patients (376 controls, 200 CRC) with reliable and complete data. Participants are required to maintain a clear fluid diet for a minimum of 4-6 hours prior to sampling and should not have received bowel preparation. Participants will be asked to provide breath samples by exhaling into single-use breath collection bags and breath will be transferred using a precision pump onto thermal desorption (TD) tubes. Breath samples will be analysed with gas chromatography-mass spectrometry in accordance with existing quality control processes.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Volatile organic compounds
  • Breath analysis
  • Volatolomics
  • Mass spectrometry
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients seen in a hospital (secondary or tertiary level care) setting

Eligibility criteria

Inclusion Criteria:

  • Patients aged ≥ 18 years referred from primary care with symptoms of suspected CRC.
  • Patients with confirmed colorectal adenocarcinoma (stages I-IV) who are treatment naïve (CRC group).

Exclusion Criteria - patients with any of the following will not be eligible for inclusion:

  • Previous surgery altering the anatomy of the lower GI tract (e.g., hemicolectomy, anterior resection).
  • Previous treatment ( chemotherapy or radiotherapy or immunotherapy) for CRC.
  • Received bowel preparation for their colonoscopy procedure.
  • History of any other cancer within three years.
  • Unable or unwilling to provide informed written consent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
720 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control group - 470 patients

    Symptomatic patients who are attending a planned colonoscopy referred under the suspected lower GI cancer pathway. Any patient who is found to have histologically-proven CRC on colonoscopy will be analysed as part of the CRC group.

    Diagnostic Test: Breath test

  • CRC group - 250 patients

    Patients who either have a confirmed diagnosis of colorectal adenocarcinoma according to a biopsy, or who are due to undergo surgical resection for suspected CRC (with histological confirmation to follow within three months).

    Diagnostic Test: Breath test

Interventions

  • Diagnostic testBreath test

    Patients must be fasted for a minimum of 4-6 hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.

06

What researchers measure

Primary outcomes

  1. Validation and further discovery of VOC biomarkers for CRC.

    GC-MS will be used to confirm the presence of certain CRC-associated VOCs in order to develop the detection model.

    Time frame: 24 months

Secondary outcomes

  1. Exploratory comparison between the breath test and FIT.

    Assessment of the performance of combining both the breath test and FIT to detect CRC.

    Time frame: 24 months

07

Study locations

3 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Apr 2026, 42 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 42 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Sep 23, 2022
Primary completionEst.
Apr 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05844514
Collaborators
National Institute for Health Research, United Kingdom, Chelsea and Westminster NHS Foundation Trust, Imperial College Healthcare NHS Trust, Royal Marsden NHS Foundation Trust, London North West Healthcare NHS Trust
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Sep 23, 2022
Primary completion
Apr 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jun 13, 2025

Study contacts

Mr Michael G Fadel, BSc MBBS MRCS
Contact
m.fadel@imperial.ac.uk
+44 (0)20 7594 3396
Professor George B Hanna, PhD FRCS
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion